HAIKOU CITY, China, April 29 China PharmaHoldings, Inc. (NYSE Amex: CPHI) ("China Pharma" or the "Company"), a leadingfully-integrated specialty pharmaceuticals company in China, today announcedthat it has retained CCG Investor Relations to design and execute its investorrelations campaign.
"We look forward to working with CCG to establish more effective andtransparent communications channels with the U.S. investment community," saidMs. Zhilin Li, Chief Executive Officer and President of China Pharma. "Byleveraging CCG's unique global platform, extensive investor network andexpertise, we hope to raise our profile among investors by clearly definingand articulating our compelling business strategy and growth outlook. We planto continue to deliver consistent and superior results to return value to ourshareholders."
China Pharma offers a portfolio of 20 generic and brand prescription drugsthrough its national distribution network covering 30 municipalities andprovinces throughout China. The Company's experienced management team iscommitted to investing in its product portfolio to commercialize and launchnew products that can drive sustainable long-term growth. The Company boastseight Good Manufacturing Production (GMP) certified product lines and has theability to manufacture drugs in a variety of dosage forms, including freezedried, liquid injectables, capsules, tablets and granules. China Pharma iswell positioned to benefit from China's rapidly growing pharmaceutical marketand implementation of the unprecedented government-led healthcare reform toprovide universal healthcare coverage.
For the year ended December 31, 2009, China Pharma's revenue increased 21%year-over-year to $61.7 million and net income rose 13% year-over-year to$20.2 million. The Company expects revenue to grow 20% to 25% in 2010.
"China Pharma has distinguished itself in the industry by building asuperior business model and focusing on high-margin quality products," saidCrocker Coulson, President of CCG Investor Relations. "The Companydifferentiates itself from peers by executing with their strategy to capturehigh margin, high quality pharmaceutical products and make strategicacquisitions to enhance opportunities to gain market share. We are confidentthat China Pharma will continue deliver robust growth in the years ahead andlook forward to assisting the Company to extend its execution track record."
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a rapidly growing specialty pharmaceuticalcompany that develops, manufactures and markets a diversified portfolio ofproducts focused on conditions with a high incidence and high mortality ratesin China, including cardiovascular, CNS, infectious, and digestive diseases.The Company's cost-effective, high margin business model is driven by marketdemand and supported by eight scalable GMP-certified product lines coveringthe major dosage forms. In addition, the Company has a broad and expandingnationwide distribution network across 30 provinces, municipalities andautonomous regions. The Company's wholly owned subsidiary, Hainan HelpsonMedical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province.For more information about China Pharma Holdings, Inc., please visithttp://www.chinapharmaholdings.com .
About CCG Investor Relations
CCG is a leading global investor relations and strategic communicationsconsulting firm. In business for more than 30 years, the agency provides acomplete range of investor communications, counseling, and IT and datasolutions through our global network to over 300 clients across multiplecapital markets. CCG has been awarded a number of industry honors for itshandling of complex investor relations and crisis communications matters. Theagency's corporate headquarters is in Los Angeles with additional offices inNew York, Beijing, Shanghai, Hong Kong, Frankfurt, Sao Paulo and Tel Aviv. Forfurther information, contact CCG directly, or visit the Company's web sites athttp://www.ccgir.com and http://www.ccgirasia.com .
Safe Harbor Statement under the Private Securities Litigation Reform Actof 1995
Certain statements in this press release constitute forward-lookingstatements for purposes of the safe harbor provisions under The PrivateSecurities Litigation Reform Act of 1995. Any statements set forth above thatare not historical facts are forward-looking statements that involve risks anduncertainties that could cause actual results to differ materially from thosein the forward-looking statements, which may include, but are not limited to,such factors as success of new product development, unanticipated changes inproduct demand, increased competition, downturns in the Chinese economy,uncompetitive levels of research and development, and other informationdetailed from time to time in the Company's filings and future filings withthe United States Securities and Exchange Commission. The forward-lookingstatements made herein speak only as of the date of this press release and theCompany undertakes no duty to update any forward-looking statement to conformthe statement to actual results or changes in the company's expectations.For more information, please contact: China Pharma Holdings, Inc. Phone: +86-898-6681-1730 (China) Email: email@example.com CCG Investor Relations Lei Huang, Account Manager Phone: +1-646-833-3417 (New York) Email: firstname.lastname@example.org Vivian Chen, Sr. Market Intelligence Exec. Phone: +1-646-701-7445(New York) Email: email@example.com
SOURCE China Pharma Holdings, Inc.